Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Mitochondrial DNA Mutations Drive Tumor Heterogeneity in Papillary Thyroid Carcinoma

ABSTRACT: Tumor heterogeneity presents a major challenge to understanding cancer evolution and therapeutic resistance in thyroid cancer. While previous studies have focused on nuclear driver mutations, the role of mitochondrial DNA (mtDNA) alterations in this heterogeneity remains elusive. Through multi-regional whole-genome and transcriptome sequencing of aggressive papillary thyroid carcinoma (PTC), we reveal that mtDNA mutations exhibit significant spatial and evolutionary heterogeneity, contrasting with conserved nuclear drivers. High mtDNA mutation burden correlated with increased mitochondrial gene expression, tumor dedifferentiation, and immune pathway activation via damage-associated molecular pattern signaling. This burden further remodeled the tumor microenvironment, favoring pro-inflammatory epithelial states over normal stromal populations. Clinically, these features were associated with reduced disease-free survival. Our findings identify mtDNA mutations as key drivers of heterogeneity and immune remodeling in PTC, suggesting mitochondrial mutational burden as a potential prognostic biomarker and therapeutic target.

ORGANISM(S): Homo sapiens

PROVIDER: GSE317520 | GEO | 2026/07/15

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Accumulated mtDNA mutations specifically impair complex I-linked respiration

Project description:Oxidative phosphorylation (OxPhos) within mitochondria relies on the coordinated synthesis of both nuclear- and mitochondrial-encoded protein subunits comprising the mitochondrial respiratory complexes (Complexes I–V). Mitochondrial DNA (mtDNA) encodes 13 proteins vital for Complex I, III, IV, and V function. Accumulated mutations in mtDNA are causally linked to aging and several age-related diseases, presumably as a consequence of impaired respiration. However, how high mtDNA mutation burden impinges on cellular bioenergetics across the major organ systems remains only partially resolved. Due to the growing links connecting mtDNA mutations to human pathophysiology, here we leveraged a comprehensive mitochondrial phenotyping platform to assess the phenotypic consequences of increased mtDNA mutation burden across tissues (brown adipose, brain, colon, heart, kidney, liver, lung, and bone marrow-derived mononuclear cells) of the mouse. Remarkably, despite widespread reductions in OxPhos protein expression, mitochondrial respiratory capacity under mixed substrate conditions was largely preserved across tissues. More detailed analysis revealed that NAD-linked respiration exhibited partial functional deficits in most tissues, consistent with functional deficiencies in complex I. In contrast, respiration routed from CII-CIII-CIV-CV remained intact. Together, these findings highlight Complex I as the primary functional consequence of mtDNA mutational load.

2026-02-19 | PXD068316 | JPOST Repository

MitoExome Sequencing of Mitochondrial OXPHOS Diseases (MGH)

Project description: Human disorders of mitochondrial oxidative phosphorylation (OXPHOS) represent a devastating collection of inherited diseases. These disorders impact at least 1:5000 live births, and are characterized by multi-organ system involvement. They are characterized by remarkable locus heterogeneity, with mutations in the mtDNA as well as in over 77 nuclear genes identified to date. It is estimated that additional genes may be mutated in these disorders. To discover the genetic causes of mitochondrial OXPHOS diseases, we performed targeted, deep sequencing of the entire mitochondrial genome (mtDNA) and the coding exons of over 1000 nuclear genes encoding the mitochondrial proteome. We applied this 'MitoExome' sequencing to 124 unrelated patients with a wide range of OXPHOS disease presentations from the Massachusetts General Hospital Mitochondrial Disorders Clinic. The 2.3Mb targeted region was captured by hybrid selection and Illumina sequenced with paired 76bp reads. The total set of 1605 targeted nuclear genes included 1013 genes with strong evidence of mitochondrial localization from the MitoCarta database, 377 genes with weaker evidence of mitochondrial localization from the MitoP2 database and other sources, and 215 genes known to cause other inborn errors of metabolism. Approximately 88% of targeted bases were well-covered (>20X), with mean 200X coverage per targeted base.

| phs000339 | dbGaP

Whole-genome sequencing of Saccharomyces cerevisiae CEN.PK2-1C subjected to mtDNA base editing or Mito-BE screen

Project description:To identify mutations that occurred in the nuclear and mitochondrial DNA of the yeast subjected to mtDNA base editing or Mito-BE screen, we performed whole-genome sequencing of cultured yeast cells after isolation of mitochondrial DNA.

2024-11-01 | E-MTAB-13701 | biostudies-arrayexpress

Rewriting nuclear epigenetic scripts in mitochondrial diseases as a strategy for heteroplasmy control

Project description:Mitochondrial diseases, caused by mutations in either nuclear or mitochondrial DNA (mtDNA), currently have limited treatment options. For mtDNA mutations, reducing mutant-to-wild-type mtDNA ratio (heteroplasmy shift) is a promising therapeutic option, though current approaches face significant challenges. Previous research has shown that severe mitochondrial dysfunction triggers an adaptive nuclear epigenetic response, characterized by changes in DNA methylation, which does not occur or is less important when mitochondrial impairment is subtle. Building on this, we hypothesized that targeting nuclear DNA methylation could selectively compromise cells with high levels of mutant mtDNA, favor ones with lower mutant load and thereby reduce overall heteroplasmy.

2025-07-02 | GSE300902 | GEO

Expression profiling by small RNA-seq for identifying miRNAs associated with pathological classifications in thyroid cancer.

Project description:There are no reliable small molecules to accurately differentiate indolent thyroid tumors from more aggressive thyroid cancers. This study aimed to develop new micro RNA (miRNA) markers for diagnosis and recurrence risk stratification of papillary thyroid carcinoma (PTC). Thyroid tumor-specific miRNA profiling was investigated in 34 fresh frozen tissues, which included nontumor (n = 7), noninvasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTP, n = 6) and PTC (n = 21), based on small RNA-seq technique. The PTC samples also consists of a number of pathological sub-cateories including classic (n = 11), tall cell (n = 7), and encapsulated follicular variant (EFV, n = 3) subtypes. By applying unsupervised hierarchical clustering with miRNAs, we found that thyroid tumor samples were well differentiated from normal thyroid tissues. When the histological data were compared among the tumor samples, patients with NIFTP or EFV were found to be differently clustered from those with classic or tall cell, indicating that micro-environment displayed by miRNAs well reflect pathological characteristics.

2021-03-03 | GSE159330 | GEO

Mesenchymal Stem Cells Transfer Mitochondria to the Cells with Virtually Absent Mitochondrial Function but Not to the Cells Harboring Pathogenic Mitochondrial DNA Mutations

Project description:It has been reported that human mesenchymal stem cells (MSCs) can transfer mitochondria to the cells with severely compromised mitochondrial function. We tested whether MSCs transfer mitochondria to the cells under several different conditions of mitochondrial dysfunction, including human pathogenic mitochondrial DNA (mtDNA) mutations. Using biochemical selection methods, we found that exponentially growing cells in restrictive media (uridine and bromodeoxyuridine [BrdU]+) after coculture of MSCs (uridine-independent and BrdU-sensitive) and 143B-derived cells with severe mitochondrial dysfunction induced by either long-term ethidium bromide treatment or short-term rhodamine 6G (R6G) treatment (uridine-dependent but BrdU-resistant). The exponentially growing cells had nuclear DNA fingerprint patterns identical to 143B, and a sequence of mtDNA identical to the MSCs. Since R6G causes rapid and irreversible damage to mitochondria without the removal of mtDNA, the mitochondrial function appears to be restored through a direct transfer of mitochondria rather than mtDNA alone. Conditioned media, which were prepared by treating mtDNA-less 143B 0 cells under uridine-free condition, induced increased chemotaxis in MSC, which was also supported by transcriptome analysis. A chemotaxis inhibitory agent blocked mitochondrial transfer phenomenon in the above condition. However, we could not find any evidence of mitochondrial transfer to the cells harboring human pathogenic mtDNA mutations (A3243G mutation or 4,977 bp deletion). Thus, the mitochondrial transfer is limited to the condition of a near total absence of mitochondrial function. Elucidation of the mechanism of mitochondrial transfer will help us create a potential “cell therapy-based mitochondrial restoration or mitochondrial gene therapy” for human diseases caused by mitochondrial dysfunction. time series

2011-11-22 | E-GEOD-33831 | biostudies-arrayexpress

Differential protein expression profile of papillary thyroid carcinoma with and without lymph node metastasis

Project description:Papillary thyroid carcinoma (PTC), the most common form of thyroid carcinomas, is a well-differentiated tumor and accounts for about 80% of all thyroid carcinomas. With the advantage of providing comprehensively analysis of global proteins in samples, proteomics techniques are increasingly applied in the field of identifying novel biomarkers in thyroid cancer. In this study, we conducted a TMT labeling-based quantitative proteomics analysis and bioinformatics analysis to compare the alternation of global proteins in tumor tissues and para-tumor tissues between PTC with LNM and without LNM.

2022-03-03 | PXD003225 | Pride

MitoPerturb-Seq identifies gene-specific single-cell responses to mitochondrial DNA depletion and heteroplasmy [DamID]

Project description:Mitochondria contain their own genome, the mitochondrial DNA (mtDNA), which is under strict control of the cell nucleus. mtDNA occurs in many copies in each cell, and mutations often only affect a proportion of them, giving rise to heteroplasmy. mtDNA copy number and heteroplasmy level together shape the cell- and tissue-specific impact of mtDNA mutations, ultimately giving rise to rare mitochondrial and common neurodegenerative diseases. However, little is known about how copy number and heteroplasmy interact within single cells, and how this is regulated by the nuclear genes and pathways that sense and control them. Here we describe MitoPerturb-Seq for CRISPR/Cas9-based high-throughput single-cell interrogation of the impact of nuclear gene perturbation on mtDNA copy number and heteroplasmy. We screened a panel of nuclear mtDNA maintenance genes in cells with heteroplasmic mtDNA mutations. This revealed both common and perturbation-specific aspects of the integrated stress-response to mtDNA depletion, that were only partially mediated by Atf4, and caused cell-cycle stage-independent slowing of cell proliferation. MitoPerturb-Seq thus provides novel experimental insight into disease-relevant mito-nuclear interactions, ultimately informing development of novel therapies targeting cell- and tissue-specific vulnerabilities to mitochondrial dysfunction.

2026-01-27 | GSE297491 | GEO

MitoPerturb-Seq identifies gene-specific single-cell responses to mitochondrial DNA depletion and heteroplasmy [RNA-Seq]

2026-01-27 | GSE297416 | GEO

MitoPerturb-Seq identifies gene-specific single-cell responses to mitochondrial DNA depletion and heteroplasmy [multiome]

2026-01-27 | GSE297418 | GEO